The Role of Alemtuzumab in the Management of T-Cell Malignancies

Seminars in Oncology

Volumn 33, Issue SUPPL. 5, 2006, Pages 44-52

  Dearden, Claire ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ARSENIC TRIOXIDE; BEXAROTENE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; FLUDARABINE; INTERFERON; MITOXANTRONE; PENTOSTATIN; T LYMPHOCYTE RECEPTOR; ZIDOVUDINE;

ARTICLE; ATAXIA TELANGIECTASIA; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL FEATURE; CLINICAL TRIAL; CYTOGENETICS; DRUG EFFICACY; EPSTEIN BARR VIRUS; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA; LYMPHATIC LEUKEMIA; LYMPHOMA; PRIORITY JOURNAL; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE; VIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, T-CELL; LYMPHOMA, T-CELL; NEOADJUVANT THERAPY; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 33646595621     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.01.029     Document Type: Article

References (103)

1. Goldrath A.W., and Bevan M.J. Selecting and maintaining a diverse T-cell repertoire. Nature 402 (1999) 255-262
2. Bommhardt U., Beyer M., Hunig T., et al. Molecular and cellular mechanisms of T cell development. Cell Mol Life Sci 61 (2004) 263-280
3. Jaffe E.S., Krenacs L., and Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol 40 (2003) 175-184
4. Brito-Babapulle V., and Catovsky D. Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet 55 (1991) 1-9
5. Matutes E., Brito-Babapulle V., Swansbury J., et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78 (1991) 3269-3274
6. Ginaldi L., De Martinis M., Matutes E., et al. Levels of expression of CD52 in normal and leukemic B and T cells. correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 22 (1998) 185-191
7. Sugimoto T., Imoto S., Matsuo Y., et al. T-cell receptor gammadelta T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype. Ann Hematol 80 (2001) 749-751
8. Stilgenbauer S., Schaffner C., Litterst A., et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 3 (1997) 1155-1159
9. Stoppa-Lyonnet D., Soulier J., Lauge A., et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood 91 (1998) 3920-3926
10. Yuille M.A., and Coignet L.J. The ataxia telangiectasia gene in familial and sporadic cancer. Recent Results Cancer Res 154 (1998) 156-173
11. Yamaguchi M., Yamamoto K., Miki T., et al. T-cell prolymphocytic leukemia with der(11)t(1;11)(q21;q23) and ATM deficiency. Cancer Genet Cytogenet 146 (2003) 22-26
12. Virgilio L., Narducci M.G., Isobe M., et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci U S A 91 (1994) 12530-12534
13. Madani A., Choukroun V., Soulier J., et al. Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. Blood 87 (1996) 1923-1927
14. Laine J., Kunstle G., Obata T., et al. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 6 (2000) 395-407
15. Herling M., Khoury J.D., Washington L.T., et al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 104 (2004) 328-335
16. Soulier J., Pierron G., Vecchione D., et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer 31 (2001) 248-254
17. Kojima K., Kobayashi H., Imoto S., et al. 14q11 abnormality and trisomy 8q are not common in Japanese T-cell prolymphocytic leukemia. Int J Hematol 68 (1998) 291-296
18. Mercieca J., Matutes E., Dearden C., et al. The role of pentostatin in the treatment of T-cell malignancies. analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 12 (1994) 2588-2593
19. Delgado J., Bustos J.G., Jimenez M.C., et al. Are activation markers (CD25, CD38 and CD103) predictive of sensitivity to purine analogues in patients with T-cell prolymphocytic leukemia and other lymphoproliferative disorders?. Leuk Lymphoma 43 (2002) 2331-2334
20. Pawson R., Dyer M.J., Barge R., et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 15 (1997) 2667-2672
21. Dearden C.E., Matutes E., Cazin B., et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98 (2001) 1721-1726
22. Keating M.J., Cazin B., Coutre S., et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 20 (2002) 205-213
23. Dearden C., Matutes E., Cazin B., et al. Very high response rates in previously untreated T-cell Prolymphocytic leukaemia patients receiving alemtuzumab (Campath-1H) therapy. Blood 102 (2003) 2378 (abstr 2378)
24. Hopfinger G., Kandler G., Koller E., et al. T-PLL-1 Protocol of the German CLL Study Group (GCLLSG) - A prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation as first line treatment in T-PLL. Blood 102 (2003) 2495 (abstr)
25. Krishnan B., Swansbury J., Cazin B., et al. Clinical outcome of stem cell transplantation (SCT) in patients with T cell prolymphocytic leukaemia (T-PLL) previously treated with alemtuzumab. A multicentre experience (2005) Abstract presented at the American Society of Hematology, December 10, Atlanta, GA (abstr 2541)
26. Absi A., His E., and Kalaycio M. Prolymphocytic leukemia. Curr Treat Options Oncol 6 (2005) 197-208
27. Lamy T., and Loughran Jr. T.P. Current concepts. Large granular lymphocyte leukemia. Blood Rev 13 (1999) 230-240
28. Dang N.H., Aytac U., Sato K., et al. T-large granular lymphocyte lymphoproliferative disorder. Expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition. Br J Haematol 121 (2003) 857-865
29. Tsang W.Y., Chan J.K., Yip T.T., et al. In situ localization of Epstein-Barr virus encoded RNA in non-nasal/nasopharyngeal CD56-positive and CD56-negative T-cell lymphomas. Hum Pathol 25 (1994) 758-765
30. Wong K.F., Chan J.C., Liu H.S., et al. Chromosomal abnormalities in T-cell large granular lymphocyte leukaemia. Report of two cases and review of the literature. Br J Haematol 116 (2002) 598-600
31. Man C., Au W.Y., Pang A., et al. Deletion 6q as a recurrent chromosomal aberration in T-cell large granular lymphocyte leukemia. Cancer Genet Cytogenet 139 (2002) 71-74
32. Skacel M., Maciejewski J., Kandil D., et al. Recurrent genomic imbalances in T-cell large granular lymphocytes (T-LGL) leukemia detected by array-based comparative genomic hybridization (CGH). Blood 102 (2003) 4768 (abstr)
33. Bigouret V., Hoffmann T., Arlettaz L., et al. Monoclonal T-cell expansions in asymptomatic individuals and in patients with large granular leukemia consist of cytotoxic effector T cells expressing the activating CD94:NKG2C/E and NKD2D killer cell receptors. Blood 101 (2003) 3198-3204
34. Siu L.L., Wong K.F., Chan J.K., et al. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol 155 (1999) 1419-1425
35. Saunthararajah Y., Molldrem J.L., Rivera M., et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease. Clinical and pathophysiological features. Br J Haematol 112 (2001) 195-200
36. Loughran Jr. T.P., Kidd P.G., and Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 84 (1994) 2164-2170
37. Osuji N., Del Giudice I., Matutes E., et al. Treatment of T-cell large granular lymphocytic leukaemia. The role for methotrexate and cyclosporin A in new, relapsed and refractory cases. Blood 102 (2003) 1467 (abstr)
38. Sternberg A., Eagleton H., Pillai N., et al. Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity. Br J Haematol 120 (2003) 699-701
39. Ru X., and Liebman H.A. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol 123 (2003) 278-281
40. Rosenblum M.D., LaBelle J.L., Chang C.C., et al. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood 103 (2004) 1969-1971
41. Bekkenk M.W., Jansen P.M., Meijer C.J., et al. CD56+ hematological neoplasms presenting in the skin. A retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 15 (2004) 1097-1108
42. Shapiro M., Wasik M.A., Junkins-Hopkins J.M., et al. Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen. Am J Hematol 74 (2003) 46-51
43. Ebihara Y., Manabe A., Tanaka R., et al. Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein-Barr virus (CAEBV) infection with allogeneic bone marrow transplantation. Bone Marrow Transplant 31 (2003) 1169-1171
44. Hyakuna N., Toguchi S., Higa T., et al. Childhood blastic NK cell leukemia successfully treated with L-asparagenase and allogeneic bone marrow transplantation. Pediatr Blood Cancer 42 (2004) 631-634
45. Okamura T., Kishimoto T., Inoue M., et al. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant 31 (2003) 105-111
46. Mahieux R., and Gessain A. HTLV-1 and associated adult T-cell leukemia/lymphoma. Rev Clin Exp Hematol 7 (2003) 336-361
47. Gotoh Y.I., Sugamura K., and Hinuma Y. Healthy carriers of a human retrovirus, adult T-cell leukemia virus (ATLV). Demonstration by clonal culture of ATLV-carrying T cells from peripheral blood. Proc Natl Acad Sci U S A 79 (1982) 4780-4782
48. Portis T., Harding J.C., and Ratner L. The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. Blood 98 (2001) 1200-1208
49. Iwanaga R., Ohtani K., Hayashi T., et al. Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I. Oncogene 20 (2001) 2055-2067
50. Kohno T., Moriuchi R., Katamine S., et al. Identification of genes associated with the progression of adult T cell leukemia (ATL). Jpn J Cancer Res 91 (2000) 1103-1110
51. Arima N., and Tei C. HTLV-I Tax related dysfunction of cell cycle regulators and oncogenesis of adult T cell leukemia. Leuk Lymphoma 40 (2001) 267-278
52. Kamada N., Sakurai M., Miyamoto K., et al. Chromosome abnormalities in adult T-cell leukemia/lymphoma. A karyotype review committee report. Cancer Res 52 (1992) 1481-1493
53. Seiki M., Eddy R., Shows T.B., et al. Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells. Nature 309 (1984) 640-642
54. Yamada Y., Tomonaga M., Fukuda H., et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma. Japan Clinical Oncology Group Study 9303. Br J Haematol 113 (2001) 375-382
55. Matutes E., Taylor G.P., Cavenagh J., et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma. Response and outcome in 15 patients. Br J Haematol 113 (2001) 779-784
56. White J.D., Wharfe G., Stewart D.M., et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 40 (2001) 287-294
57. Hermine O., Allard I., Levy V., et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 3 (2002) 276-282
58. Hermine O., Dombret H., Poupon J., et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 5 (2004) 130-134
59. Ishida T., Lida S., Akatsua Y., et al. CCR4. Chemokine receptor as a novel molecular target for immunotherapy in adult T-cell leukemia/lymphoma (ATLL). Blood 102 (2003) 3348 (abstr 3348)
60. Zhang Z., Zhang M., Goldman C.K., et al. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res 63 (2003) 6453-6457
61. Taylor P.G., and Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 24 (2005) 6047-6057
62. Porcu P., Mone A., Puhalla S., et al. Durable complete response of the human T-cell leukemia virus (HTLV-1) viral load (VL) with alemtuzumab in refractory adult T-cell leukemia (ATL). J Clin Oncol 28 (2005) 6639 (abstr)
63. Whittam L.R., Calonje E., Orchard G., et al. CD8-positive juvenile onset mycosis fungoides. An immunohistochemical and genotypic analysis of six cases. Br J Dermatol 143 (2000) 1199-1204
64. Scarisbrick J.J., Woolford A.J., Russell-Jones R., et al. Allelotyping in mycosis fungoides and Sezary syndrome. Common regions of allelic loss identified on 9p, 10q, and 17p. J Invest Dermatol 117 (2001) 663-670
65. Herrmann J.J., Roenigk Jr. H.H., Hurria A., et al. Treatment of mycosis fungoides with photochemotherapy (PUVA). Long-term follow-up. J Am Acad Dermatol 33 (1995) 234-242
66. McGinnis K.S., Junkins-Hopkins J.M., Crawford G., et al. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma. Clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol 50 (2004) 375-379
67. Kuzel T.M., Roenigk Jr. H.H., Samuelson E., et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol 13 (1995) 257-263
68. Rupoli S., Barulli S., Guiducci B., et al., Cutaneous-T Cell Lymphoma Multicenter Study Group. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides. Results of a multicenter study. Haematologica 84 (1999) 809-813
69. Chiarion-Sileni V., Bononi A., Fornasa C.V., et al. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer 95 (2002) 569-575
70. Duvic M., Hymes K., Heald P., et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma. Multinational phase II-III trial results. J Clin Oncol 19 (2001) 2456-2471
71. Wollina U., Dummer R., Brockmeyer N.H., et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98 (2003) 993-1001
72. Scarisbrick J.J., Child F.J., Clift A., et al. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol 144 (2001) 1010-1015
73. Dearden C., Matutes E., and Catovsky D. Pentostatin treatment of cutaneous T-cell lymphoma. Oncology (Huntingt) 14 (2000) 37-40
74. Kuzel T.M., Hurria A., Samuelson E., et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 87 (1996) 906-911
75. Kong L.R., Samuelson E., Rosen S.T., et al. 2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders. Leuk Lymphoma 26 (1997) 89-97
76. Foss F.M., Ihde D.C., Linnoila I.R., et al. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol 12 (1994) 2051-2059
77. Saleh M.N., LeMaistre C.F., Kuzel T.M., et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 39 (1998) 63-73
78. Olsen E., Duvic M., Frankel A., et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19 (2001) 376-388
79. Obitz E., Kim Y.H., Iversen L., et al. HuMax-CD4, a fully human monoclonal antibody. early results of an ongoing phase II trial in cutaneous T cell lymphoma (CTCL). Blood 102 (2003) 2383 (abstr)
80. Lundin J., Osterborg A., Brittinger G., et al., European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas. A phase II multicenter study. J Clin Oncol 16 (1998) 3257-3263
81. Kennedy G.A., Seymour J.F., Wolf M., et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol 71 (2003) 250-256
82. Foukaneli T., Marsh J., Pettegell R., et al. Sezary syndrome responds to treatment with Campath-1H. Blood 98 (2001) 556 (abstr)
83. Capalbo S., Delia M., Dargenio M., et al. Mycosis fungoides/Sezary syndrome. A report of three cases treated with Campath-1H as salvage treatment. Med Oncol 20 (2003) 389-396
84. Lenihan D.J., Alencar A.J., Yang D., et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 104 (2004) 655-658
85. Lundin J., Kennedy B., Dearden C., et al. Correspondence. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome. Blood 105 (2005) 4148-4149
86. Weder P., Anliker M., Itin P., et al. Familial cutaneous mycosis fungoides. Successful treatment with a combination of gemcitabine and alemtuzumab. Dermatology 208 (2004) 281-283
87. Barry T.S., Jaffe E.S., Sorbara L., et al. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol 27 (2003) 1513-1522
88. Ruco L.P., Di Napoli A., Pilozzi E., et al. Peripheral T cell lymphoma with cytotoxic phenotype. An emerging disease in HIV-infected patients?. AIDS Res Hum Retroviruses 20 (2004) 129-133
89. Zettl A., Rudiger T., Konrad M.A., et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 164 (2004) 1837-1848
90. Mori A., Takao S., Pradutkanchana J., et al. High tumor necrosis factor-alpha levels in the patients with Epstein-Barr virus-associated peripheral T-cell proliferative disease/lymphoma. Leuk Res 27 (2003) 493-498
91. Dutcher J.P. The role of Epstein-Barr virus and elevated levels of tumor necrosis factor in determining prognosis in Asian peripheral T-cell lymphomas. Leuk Res 27 (2003) 467-469
92. Rassidakis G.Z., Jones D., Lai R., et al. BCL-2 family proteins in peripheral T-cell lymphomas. Correlation with tumour apoptosis and proliferation. J Pathol 200 (2003) 240-248
93. Jöhrens K. ALK-negative anaplastic large cell lymphomas represent a distinct entity. Ann Oncol 16 (2005) 512 (abstr)
94. Pellatt J., Sweetenham J., Pickering R.M., et al. A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin's lymphoma. Ann Hematol 81 (2002) 267-272
95. Musson R., Radstone C.R., Horsman J.M., et al. Peripheral T cell lymphoma. The Sheffield Lymphoma Group experience (1977-2001). Int J Oncol 22 (2003) 1363-1368
96. Lee H.K., Wilder R.B., Jones D., et al. Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. Leuk Lymphoma 43 (2002) 1769-1775
97. Weidmann E., Hess G., Krause S.W., et al. Combination chemoimmunotherapy using alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin is an effective first-line regimen in peripheral T-cell lymphomas. Blood 104 (2004) 2640 (abstr)
98. Gallamini A., Zaja F., Gargantini L., et al. CHOP chemotherapy plus Campath-1H (CHOP-C) as first line treatment in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol 16 (2005) 321 (abstr)
99. Tsimberidou A.M., Giles F., Duvic M., et al. Phase II study of pentostatin in advanced T-cell lymphoid malignancies. Update of an M.D. Anderson Cancer Center series. Cancer 100 (2004) 342-349
100. Enblad G., Hagberg H., Eriksson M., et al. A pilot study of alemtuzumab (Anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphoma. Blood 102 (2003) 2384 (abstr)
101. Rodriguez J., Caballero M.D., Gutierrez A., et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 88 (2003) 1372-1377
102. Rodriguez J., Caballero M.D., Gutierrez A., et al. Long-term follow-up of autologous stem cell transplantation (ASCT) in patients with peripheral T-cell lymphoma (PTCL). The Spanish Lymphoma Cooperative Group (GEL-TAMO) experience. Ann Oncol 16 (2005) 72 (abstr)
103. Kahl C., Leithauser M., Wolff D., et al. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. Ann Hematol 81 (2002) 646-650